• (+)-Bicuculline: Practical Protocol Guide

  2026-09-07

  This guide explains how to prepare, store, and apply (+)-Bicuculline as a GABAA receptor antagonist for studies of inhibitory neurotransmission, synaptic NMDA receptor signaling modulation, and related neuronal assays. It is intended for controlled laboratory research only, not for diagnostic, clinical, or therapeutic use, and the discussion does not substitute for directly matched publication evidence.

• AZD8055 Protocol for mTOR Pathway Studies

  2026-09-07

  AZD8055 (SKU A8214) provides a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 signaling, mTORC2 signaling, cell proliferation, and selected metabolic responses. It is suited to preclinical mechanistic work with careful DMSO-based handling, but not to projects requiring water solubility, an established clinical dosing regimen, or evidence of clinical efficacy.

• Cyclophilin A and Cyclosporine Resistance

  2026-09-05

  Colgan and colleagues used Ppia-deficient mice and immune-cell reconstitution to show that cyclophilin A is the principal intracellular mediator of cyclosporine immunosuppression. The study links loss of cyclophilin A to impaired calcineurin inhibition and resistance to suppression of allogeneic immune responses, providing a strong genetic framework for interpreting calcineurin-targeted immune response suppression.

• Tariquidar in High-Viscosity Chemoresistance Models

  2026-09-04

  Tariquidar (XR9576) helps separate P-glycoprotein-driven drug efflux from the broader effects of a mechanically altered tumor microenvironment. This practical workflow combines viscosity-controlled culture, transporter assays, and chemotherapy endpoints to improve cancer chemoresistance studies.

• REV1–DHX36 Control of G4 Replication

  2026-09-04

  The 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 partnership that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. Its findings position REV1 as a coordinator of G4 tolerance rather than only a translesion polymerase, while linking defective G4 processing to amplified ATM/ATR signaling and drug sensitivity.

• 2X HyperFusion High-Fidelity Master Mix Workflows

  2026-09-03

  Build faster, more accurate PCR workflows for cloning, CRISPR construct verification, and difficult templates with a proofreading master mix. This guide connects practical amplification decisions to the bufalin–CRISPR/Cas9 nanomedicine study while separating validated product specifications from research-stage assay recommendations.

• Berberine Hydrochloride: From Gut Signals to Bone

  2026-09-03

  Berberine hydrochloride connects metabolic signaling with gut–bone axis research through AMPK activation, microbial butyrate production, and osteoimmune regulation. This article presents a causal assay framework that extends beyond standard workflow and translational summaries.

• Toremifene Citrate: Clinical Pharmacology and Research

  2026-09-02

  The reference paper presents toremifene citrate as a nonsteroidal antiestrogen and oral selective estrogen receptor modulator, integrating mechanism, clinical positioning, pharmacokinetics, safety monitoring, and nursing considerations. Its practical value lies in showing how receptor biology, comparative evidence with tamoxifen, metabolism, drug interactions, and patient selection should shape breast cancer research and translational study design.

• Realgar Neurotoxicity and the Liver–Brain Ornithine Axis

  2026-09-02

  A 2025 Advanced Science study identifies a liver–brain mechanism in which realgar-derived arsenic inhibits hepatic OTC, elevates ornithine, and promotes ZBTB7A-dependent suppression of astrocyte glycolysis. The findings connect disrupted urea cycle metabolism with frontal-lobe energy failure and behavioral deficits, while offering a framework for studying ornithine-dependent neurotoxicity.

• CX-4945 (Silmitasertib): CK2 Research Guide

  2026-09-01

  CX-4945, also called Silmitasertib, is a selective ATP-competitive CK2 inhibitor used to study PI3K/Akt signaling, apoptosis, and context-dependent cell-cycle control. Product data and a 2026 ischemic-stroke study support CX-4945 as a mechanistic CK2 probe, but they do not establish a universal anticancer or clinical treatment effect.

• Ac-YVAD-CMK for Membrane-Inflammation Dissection

  2026-09-01

  Ac-YVAD-CMK enables mechanistic separation of caspase-1-driven inflammation from plasma-membrane repair in Kupffer cell and Listeria models. This article translates TMEM16F research into a decision framework for interpreting cytokines, pyroptosis, and liver injury data.

• AZD2461: A Novel PARP Inhibitor Workflow

  2026-08-31

  AZD2461 is a novel PARP inhibitor for connecting PARP-1 suppression with DNA damage response, cell-cycle arrest, and cancer-cell killing. A paired viability-and-death workflow helps distinguish true cytotoxicity from reversible growth inhibition while testing resistance biology in breast cancer models.

• DON Liver Injury: Mitophagy and Nrf2 Signaling

  2026-08-31

  This study proposes that deoxynivalenol-induced liver injury is driven by excessive PINK1/Parkin-mediated mitophagy together with suppression of the p62–Keap1–Nrf2 cytoprotective pathway. Mouse and AML-12 cell experiments, including pathway inhibition and p62 rescue, provide a mechanistic framework for interpreting mitochondrial damage, oxidative stress, inflammation, apoptosis, and lipid metabolic disruption.

• AZD2461: A Better Way to Read PARP Responses

  2026-08-30

  AZD2461 is a novel PARP inhibitor for dissecting DNA repair pathway modulation, drug resistance, and response kinetics in breast cancer models. This guide pairs its mechanistic profile with a rigorous framework for separating growth inhibition from true cell killing in vitro.

• VX-661: F508del CFTR Corrector Workflow

  2026-08-29

  Build more interpretable cystic fibrosis research assays with VX-661 by separating CFTR trafficking rescue from channel potentiation. This workflow combines practical dosing, orthogonal surface-expression and function readouts, and calnexin-aware controls for variant-specific optimization.

7806 records 1/521 page Next 12345 下5页 Last page